Product Images Oxaliplatin

This appears to be a statistical analysis of a medical study that compares the effectiveness of two treatments, FOLFOX4 and LVSFUZ, in terms of disease-free survival (DFS) over a period of 72 months. The hazard ratio, confidence interval, and stratified Logrank test are reported. The graph shows the probability of DFS over time, as well as the number of patients at risk in each treatment arm.*

This is a graph or a chart that represents the probability of DF's probability on the Y-axis ranging from 0 to 1. The X-axis represents DFS (months), ranging from 0 to 60. The chart plots two different treatment arms, i.e., FOLFOX4, and LV5FU2, for the DUKES C type of cancer. A statistical test called Logrank Test was performed with p-value being 0.005. The Hazard Ratio with a 95% confidence interval was 0.78 [0.65, 0.93].*

This table shows the percentage of patients surviving and median survival (in months) for different treatment combinations. There are three different treatments compared: Oxalplatin for Injection + 5-FUILV, Oxalplatin for Injection + Irinotecan, and Irinotecan + 5-FULV. The table shows that treatment with Oxalplatin for Injection + 5-FUILV has the highest percentage of patients surviving and longest median survival time. The data also suggests that there are statistically significant differences in survival rates between the treatment groups.*

Oxaliplatin is a lyophilized powder for injection, which must be diluted before use. The package insert contains information on the necessary reconstitution and dilution steps. It is important not to mix or add sodium chloride-containing solutions. The product is a cytotoxic agent and comes in 50 mg vials. The container closure does not contain natural rubber latex and is sterile, nonpyrogenic, and preservative-free. The manufacturer is Sindan Pharma SRL, and the distributer is Actavis Pharma, Inc. It must be stored at a controlled room temperature between 15-30°C (59-86°F) and discarded if unused.*